MRM Proteomics Inc. partners with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to […]
Orleans-based Tetra Bio-Pharma submits multiple applications of Orphan Drug Designation for cannabinoids to the U.S. Food and Drug Administration (FDA) for various forms of rare […]
Sierra Oncology, Inc., a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology […]
Helomics Corporation launches its new Precision Oncology Insights platform. This platform provides a personalized oncology roadmap for oncologists and their patients. The initial focus will […]
In 1986, the FDA approved a new transplant rejection drug that was derived from an intact monoclonal antibody (mAb).1 Although it would be almost a […]
Halifax-based Appili Therapeutics Inc. announces that they have received positive top-line results from a pivotal relative bioavailability study evaluating pharmacokinetics, safety, and palatability of ATI-1501 […]
Guelph-based PlantForm Corporation of Canada is stretching across the ocean to collaborate with South Africa’s Council for Scientific and Industrial Research (CSIR) and BGM Pharmaceuticals […]
Horizon Discovery announces the launch of its new cell line-derived epidermal growth factor receptor (EGFR) multiplex cell-free DNA (cfDNA) reference standard. The new reference standard […]
Over the past two decades, pharmaceutical companies have expanded their focus in new drug development efforts beyond small molecules to include large molecules or biopharmaceuticals.
TORONTO, ON – The Ontario Brain Institute (OBI) and the Movement Disorders Clinic (MDC) at Toronto’s University Health Network (UHN) have embarked on Canada’s first […]
Copyright © 2021 | WordPress Theme by MH Themes
